Medivir AB (MVIR B) - Financial and Strategic SWOT Analysis Review

Medivir AB (Medivir) is a pharmaceuticals company. It undertakes the research and development of drugs for high-value treatments of infectious diseases. The company operates through two business segments, namely, Pharmaceuticals segment and Parallel Import segment. The Pharmaceuticals segment comprises research and development of new products, manufacturing, marketing and commercialization of pharmaceuticals whereas the Parallel Import segment is engaged in importing pharmaceuticals products from other European countries. Its product portfolio is principally focused on eight therapies categorized under infectious diseases (Hepatitis C, HIV, shingles, Hepatitis B and cold sores) and other indications.(bone related, neuropathic pain and Dengue fever). The company has only one commercialized product, Xerclear targeted towards Herpes labialis. Geographically, the company operates through four subsidiaries, namely, Medivir HIV Franchise AB, Medivir Personal AB, Medivir UK Ltd. and BioPhausia AB. Medivir is headquartered in Huddinge, Sweden.

The company focuses on successful development of its existing product pipeline and expanding it to other geographic markets as well as discover new drug candidates in targeted therapeutic areas through various research and development collaborations and agreements. This intent is reflected from the recent launch of Xerclear and the completion of enrollment for the global phase-III clinical trials for TMC-435. It also acquired BioPhausia with the main focus on strengthening its commercial platform and also expanded its existing partnership with Bristol-Myers Squibb Company, for expanded clinical study program to conduct a drug-drug interaction study with TMC435 and BMS-986094.

Medivir AB Key Recent Developments

Aug 30, 2011: Medivir Announces Senior Management Changes
Aug 31, 2011: Medivir Reports Net Sales Of SEK322.9m In Q2 2011
Feb 23, 2012: Medivir Reports Net Sales Of SEK131.8m In Q4 2011
Oct 24, 2011: Medivir Reports Revenue Of SEK122.2m In Q3 2011
Sep 26, 2011: Medivir Appoints Maris Hartmanis As New CEO

This comprehensive SWOT profile of Medivir AB provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Medivir AB including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.